As deep penetrating nevi can mimic the vertical growth phase of nodular malignant melanoma, and ADA could potentially be downregulating DPP4 [133], [134] we believe that the elicitation of the complementary role of these two biomarkers to distinguish these two entities is necessary and also warrants further clinical studies. This evidence concerns the gene ADA and nodular malignant melanoma.